You are here

Article Text

Article menu
Critical care
Original article
Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)
  1. Rachel C A Dancer1,
  2. Dhruv Parekh1,
  3. Sian Lax1,
  4. Vijay D'Souza1,
  5. Shengxing Zheng1,
  6. Chris R Bassford1,
  7. Daniel Park1,
  8. D G Bartis1,
  9. Rahul Mahida1,
  10. Alice M Turner1,
  11. Elizabeth Sapey1,
  12. Wenbin Wei2,
  13. Babu Naidu1,
  14. Paul M Stewart3,
  15. William D Fraser4,
  16. Kenneth B Christopher5,
  17. Mark S Cooper6,
  18. Fang Gao1,
  19. David M Sansom7,
  20. Adrian R Martineau8,
  21. Gavin D Perkins9,
  22. David R Thickett1
  1. 1Centre for Translational Inflammation and Fibrosis Research, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
  2. 2School of Cancer Sciences, University of Birmingham, Birmingham, UK
  3. 3Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
  4. 4Norwich Medical School, University of East Anglia, Norwich, UK
  5. 5Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
  6. 6Department of Medicine, Concord Medical School, University of Sydney, Sydney, New South Wales, Australia
  7. 7Institute of Immunity and Transplantation, University College London, London, UK
  8. 8Blizard Institute, Queen Mary University of London, London, UK
  9. 9Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
  1. Correspondence to Professor David Thickett, Centre for Translational Inflammation and Fibrosis Research, Queen Elizabeth Hospital, University of Birmingham, Birmingham B15 2TH, UK; d.thickett{at}bham.ac.uk

Abstract

Rationale Vitamin D deficiency has been implicated as a pathogenic factor in sepsis and intensive therapy unit mortality but has not been assessed as a risk factor for acute respiratory distress syndrome (ARDS). Causality of these associations has never been demonstrated.

Objectives To determine if ARDS is associated with vitamin D deficiency in a clinical setting and to determine if vitamin D deficiency in experimental models of ARDS influences its severity.

Methods Human, murine and in vitro primary alveolar epithelial cell work were included in this study.

Findings Vitamin D deficiency (plasma 25(OH)D levels <50 nmol/L) was ubiquitous in patients with ARDS and present in the vast majority of patients at risk of developing ARDS following oesophagectomy. In a murine model of intratracheal lipopolysaccharide challenge, dietary-induced vitamin D deficiency resulted in exaggerated alveolar inflammation, epithelial damage and hypoxia. In vitro, vitamin D has trophic effects on primary human alveolar epithelial cells affecting >600 genes. In a clinical setting, pharmacological repletion of vitamin D prior to oesophagectomy reduced the observed changes of in vivo measurements of alveolar capillary damage seen in deficient patients.

Conclusions Vitamin D deficiency is common in people who develop ARDS. This deficiency of vitamin D appears to contribute to the development of the condition, and approaches to correct vitamin D deficiency in patients at risk of ARDS should be developed.

Trial registration UKCRN ID 11994.

  • ARDS
  • Innate Immunity

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1136/thoraxjnl-2014-206680

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key messages

    What is the key question?

    • Is vitamin D deficiency a risk factor for the development of acute respiratory distress syndrome (ARDS)?

    What is the bottom line?

    • Patients with and at risk of ARDS are highly likely to be deficient, and severity of vitamin D deficiency relates to increased epithelial damage, the development of ARDS and survival.

    Why read on?

    • We present evidence that an easily treatable vitamin deficiency may increase the risk of ARDS in patients at risk.

    Introduction

    Acute respiratory distress syndrome (ARDS) occurs due to either direct or indirect proinflammatory insults. However, only a proportion of at-risk patients develop ARDS, with research suggesting that genetic, age, social and other factors play a role in determining who develops ARDS.1

    More than 1 billion people worldwide are believed to have vitamin D deficiency.2 Vitamin D has important functions besides bone and calcium homeostasis3 with cells of the innate and adaptive immune system responding to vitamin D. Vitamin D deficiency may therefore increase the risk of bacterial and viral infection.

    Vitamin D deficiency is associated with an increased risk of intensive care admission and mortality in patients with pneumonia.4 Deficiency is common in critically ill patients and associated with adverse outcome.3 Gram-positive bacteria, invasive pneumococcal disease and meningococcal disease are more common when 25(OH)D3 levels are low.5 Recent data from an Austrian study in critically ill deficient patients suggests that when treatment with vitamin D is successful in raising levels >75 nmol/L there is a mortality benefit.6

    Vitamin D may improve outcomes by reducing both local and systemic inflammatory responses as a result of modulating cytokine responses.7 In a mouse model of lethal endotoxaemia, survival post intravenous lipopolysaccharide (LPS) was significantly poorer in the vitamin D receptor knockout mice.8

    Our aim was to define the prevalence and severity of vitamin D deficiency in patients with ARDS and to establish whether vitamin D deficiency is a risk factor for and/or a driver of the exaggerated and persistent inflammation that is a hallmark of ARDS. To achieve these aims, we employed translational clinical studies and in vitro primary cell work and murine models.

    Methods

    Patient cohorts

    Patient cohort details are outlined in the online supplement but consisted of 52 patients with ARDS, 57 patients undergoing oesophagectomy (at risk of ARDS) and 8 patients undergoing oesophagectomy who had high-dose vitamin D supplementation prior to surgery.

    Patients with ARDS: 52 patients who were recruited into the first beta agonist lung injury trial (BALTI-1) study9 and the translational sub-study of BALTI-2.10 There was no difference in age, sex, pre-enrolment Lung Injury score or acute physiology and chronic health evaluation (APACHE) II in these two groups of patients. Vitamin D levels were determined from ARDS patient plasma collected on the day of enrolment. In the oesophagectomy cohort, blood was collected on the day of the operation—pre any intervention.

    Aetiology of ARDS is outlined in table 1. As these cohorts of patients were diagnosed prior to the Berlin criteria, throughout the paper we have used ARDS to indicate patients meeting criteria for acute lung injury or ARDS according to the definition of the American European Consensus Conference.11

    View this table:
    Table 1

    Comparison of demographics between ARDS and at-risk patients who were undergoing oesophagectomy

    Pulse Contour Cardiac Output Monitoring (PiCCO)

    Extravascular lung water (EVLW) was measured using the single-indicator transpulmonary thermodilution system (PiCCO-II; Pulsion) as described previously.12 In our study, the coefficient of variance for this system was <7% for all parameters.

    Vitamin D status: 25(OH)D3 was measured by tandem mass spectroscopy using appropriate Vitamin D External Quality Assessment Scheme control. 1,25(OH)2D and vitamin D binding protein (VDBP) were measured by ELISA. Definition of vitamin D status is controversial, with different figures used throughout the literature, but for this study we have considered plasma 25-OH vitamin D3 levels <50 nmol/L as deficient and levels <20 nmol/L as severe deficiency.13 ,14 In addition, patients in the at-risk cohort with 25(OH) vitamin D3 <20 nmol/L had significantly lower 1,25(OH)2 vitamin D than patients with higher levels (<20 nmol/L 74 pmol/L vs >20 nmol/L 90 pmol/L, p=0.029).

    Murine cytokines were measured by multiplex array (R&D, UK) or ELISA as per the manufacturer's instruction.

    ATII cell isolation and culture

    ATII cells were extracted from lung resection specimens according to the methods described previously15 (see online supplementary material).

    Microarray analysis is outlined in the online supplementary material.

    Wound repair, proliferation and cell death assays were performed as described previously.16

    Mouse methods

    Wild-type (WT) C57Bl/6 mice were obtained from Harlan UK, Oxford, UK, and maintained at BMSU, Birmingham University, UK. Once weaned, vitamin D deficiency was induced in WT pups by feeding them a vitamin D-deficient chow (Harlan, USA) for 6 weeks pre-intra-tracheal (IT) LPS. 25(OH)-vitamin D was assessed by direct ELISA (ImmunDiagnostik, Germany). The LPS challenge model was performed as described previously.17 Briefly, mice are anaesthetised and 50 µg LPS (Sigma, UK) instilled by IT route as a model of direct lung injury. Mice were sacrificed at neutrophilic peak, 48 h post-LPS instillation, and bronchoalveolar lavage (BAL) performed with two washes of 0.6 mL phosphate buffered saline (PBS)/EDTA (200 nM) installations to determine the local effects on inflammation. Untreated controls were also analysed to determine lung parameters in vitamin D-deficient mice. BAL fluid (BALF) was assessed for cellular inflammation by cell count, neutrophilia and neutrophil apoptosis (flow cytometry), markers of epithelial damage BALF receptor for glycosylated endpoints (BALF RAGE), protein permeability index (ratio of BALF protein:plasma protein) as well as cytokines by luminex array (R&D systems, UK). Results represent mice from three separate experiments with at least four replicates per group. Oxygen saturations were measured at 48 h post-LPS and compared with WT mice given PBS by MouseOx II Plus (n=8 for each condition). All experiments were performed in accordance with UK laws with approval of local animal ethics committee.

    Statistics Data were analysed using SPSS for Windows 16.0 (SPSS, Chicago, Illinois, USA). Data were tested for normality and analysed by unpaired t tests or Mann–Whitney U test. Data are expressed as mean (SD) unless otherwise indicated. A χ2 or Fisher’s exact test was used to compare proportions.

    To test the hypothesis that low 25(OH)D levels are associated with the development of ARDS in the at-risk oesophagectomy cohort (N=65), we performed multivariable logistic regression with the exposure of interest being 25(OH)D3 level <20 nmol/L and ARDS as the outcome. Adjusted ORs were estimated by multivariable logistic regression models with inclusion of covariate terms chosen, a priori, thought to be plausibly associated with both 25(OH)D3 level and ARDS in the oesophagectomy patient cohort. We sought to build a parsimonious model that did not unnecessarily adjust for covariates that did not affect bias or the causal relation between exposure and outcome. Model calibration was assessed using the Hosmer–Lemeshow (HL) χ2 goodness-of-fit test and the accompanying p value. Bayesian information criterion and Akaike information criterion were also used to determine global model fit. Covariates included in the logistic regression model were age, gender, diagnosis, staging and pack-years smoked. The discriminatory ability for ARDS was quantified using the c-statistic. In all analyses, p values are two-tailed and values below 0.05 were considered statistically significant.

    Results

    Plasma vitamin D status in patients with or at risk of ARDS

    Patients with ARDS (100%) were vitamin D-deficient (plasma 25(OH)D3 <50 nmol/L). In total, 55 (96%) out of 57 unsupplemented oesophagectomy patients at risk of ARDS were deficient preoperatively but levels were higher than in patients with ARDS. Both patients at risk and patients with ARDS had significantly lower levels of 25(OH)D3 than normal controls (see figure 1). Demographics of patients groups based on vitamin D levels are illustrated in table 2.

    View this table:
    Table 2

    Comparison of demographics between patients with severe deficiency, moderate deficiency and vitamin D supplemented at-risk patients undergoing oesophagectomy

    Figure 1
    Figure 1

    Plasma 25(OH)D3 levels in acute respiratory distress syndrome (ARDS) versus at risk and normal controls. The horizontal bar represents the median, and the boxes represent IQRs. Vertical lines show minimum–maximum range. Fifty-two patients with ARDS, 57 at-risk patients undergoing oesophagectomy, 18 healthy controls.

    In at-risk patients, preoperative median plasma levels of 25(OH)D3 were significantly lower in those patients who were ventilated with ARDS postoperatively (ARDS 16.97 nmol/L vs no ARDS 25.46 nmol/L, p=0.014). Oesophagectomy patients with severe vitamin D deficiency (plasma 25(OH)D3 <20 nmol/L) had a 37.5% risk of postoperative lung injury as opposed to a 15% risk with vitamin D levels >20 nmol/L (figure 2).

    Figure 2
    Figure 2

    Risk of postoperative acute respiratory distress syndrome in severe 25(OH)D3 deficiency versus less severe deficiency. Severe deficiency (n=25), less severe (n=32).

    In the at-risk oesophagectomy cohort, preoperative vitamin D status was the only measure to have a significant difference in oesophagectomy patients who develop lung injury postoperatively (see table 3).

    View this table:
    Table 3

    Univariate analysis of predictors of postoperative ARDS in patients undergoing oesophagectomy

    The odds of ARDS in patients with 25(OH)D3 <20 nmol/L was 3.5-fold that of patients with 25(OH)D3 ≥20 nmol/L (OR=3.5 (95% CI 1.06 to 11.6; p=0.040)). Following adjustment for gender, age, diagnosis, staging data, and pack-years, patients with 25(OH)D3 <20 nmol/L had a 4.2-fold higher odds of ARDS than patients with 25(OH)D <20 nmol/L (OR=4.2 (95% CI 1.13 to 15.9; p=0.032)). The adjusted model showed good calibration (HL χ2 11.10, p=0.20) and discrimination for ARDS (area under the curve 0.73). When 25(OH)D was analysed with logistic regression as a continuous exposure in 1 nmol/L increments, the odds of ARDS decreases by 17% for every 1 nmol/L decrease in 25(OH)D (OR 0.83 (95% CI 0.69 to 0.98; p=0.033)), adjusted for age, gender, diagnosis, staging and pack-years smoked.

    Plasma levels of 1,25(OH)2D are lowest in ITU non-survivors

    Median plasma 1,25(OH)2D levels were also significantly lower in patients with ARDS (35.5 pmol/L) than in at-risk patients (85 pmol/L, p=0.0001). Plasma 1,25(OH)2D was lower at admission to intensive therapy unit (ITU) in patients who died than survivors (figure 3). Plasma levels of 1,25(OH)2D were lower in oesophagectomy patients at risk of ARDS who subsequently went on to be ventilated for ARDS (68 pmol/L (IQR 47–91)) than those who did not get postoperative ARDS (89 pmol/L (IQR 76–109), p=0.007).

    Figure 3
    Figure 3

    Plasma 1,25(OH)2D was significantly higher in patients with acute respiratory distress syndrome who survived at least 28 days following admission than those who died. The horizontal bar represents the median, and the boxes represent IQRs. Vertical lines show minimum–maximum range. Died (n=32), survived (n=20).

    Plasma VDBP levels are lower in patients with ARDS.

    25(OH)D3 circulates tightly bound to the VDBP (also known as Gc-actin).18 VDBP levels were 40 mg/dL in normal controls, 19 mg/dL in ARDS and 28.7 mg/mL in the at-risk patients at the beginning of oesophagectomy (figure 4).

    Figure 4
    Figure 4

    Plasma vitamin D binding protein measured by ELISA in acute respiratory distress syndrome (ARDS) versus at risk and normal controls. Fifty-two patients with ARDS, 57 at-risk patients undergoing oesophagectomy, 18 healthy controls.

    Vitamin D levels and perioperative changes in epithelial integrity in patients at risk of ARDS

    We measured perioperative changes in an in vivo measure of the integrity of the alveolar–capillary barrier, namely EVLW accumulation (extravascular lung water index (EVLWI)) and pulmonary vascular permeability index (PVPI) using a PiCCO2 catheter19–22 and related this to the patient's vitamin D status.

    Severe vitamin D deficiency (25-(OH)D3 <20 nmol/L) was associated with an increased accumulation of EVLW as assessed by PiCCO EVLWI and evidence of increases of PVPI, a marker of alveolar capillary permeability. Patients supplemented with vitamin D prior to oesophagectomy had significantly reduced changes in PiCCO EVLWI and PVPI than unsupplemented patients (figures 5 and 6).

    Figure 5
    Figure 5

    Changes in extravascular lung water index (EVLWI) at the end of oesophagectomy and on the morning of postoperative day 1. EVLWI was measured using Pulse Contour Cardiac Output Monitoring II catheter at the end of the operation and on the morning after the operation (day 1). Severe deficient (n=25), moderate (n=32) and supplemented (n=8).

    Figure 6
    Figure 6

    Changes in Pulse Contour Cardiac Output Monitoring pulmonary vascular permeability index (PVPI) at the end of oesophagectomy and the morning of postoperative day 1. Severe deficient (n=25), moderate (n=32) and supplemented (n=8).

    Vitamin D deficiency is a determinant of inflammation and epithelial injury in the intratracheal LPS murine model of ALI/ARDS

    We studied the response to 50 µg of IT LPS in WT or mice made vitamin D deficient by dietary manipulation. Deficient mice were fed a vitamin D-free diet for 6 weeks and had median plasma vitamin 25(OH)D3 levels of 8 nmol/L (SEM 1.15 nmol/L) vs 42 nmol/L (SEM 2.17 nmol/L) in WT (p=0.001). Untreated vitamin D-deficient mice had no observed lung damage or inflammation (figure 7, and data not shown).

    Figure 7
    Figure 7

    Lung injury and inflammation was significantly higher in vitamin D-deficient mice compared with wild-type (WT) following intra-tracheal (IT)-lipopolysaccharide (LPS). Levels of tumour necrosis factor-α and CXCL1/KC in UTCs were below the detection threshold of the assays performed. UTC, untreated control; N.D., not detected.

    Following LPS challenge, vitamin D-deficient mice had increased evidence of alveolar epithelial damage as measured by BALF RAGE and BALF permeability index (figure 7A). Cellular inflammation and neutrophil apoptosis in BALF were also elevated in vitamin D-deficient mice, along with release of proinflammatory cytokines tumour necrosis factor-α, CXCL1/KC and vascular endothelial growth factor (figure 7B and C, respectively). These changes resulted in significantly lower oxygen saturation as measured by pulse oximetry (figure 7C), which we have previously demonstrated as a physiological measure of murine lung function.15

    Vitamin D is trophic for alveolar epithelial cells in vitro

    ATII cells were treated with 100 nmol/L of 25(OH)D3 for 24 h. Microarray analysis revealed that vitamin D treatment caused a sustained activation or inhibition of 660 genes that included pathways involved in vitamin metabolism as well as regulators of cell growth, differentiation and response to wounding (GEOSET record GSE46749). The online supplementary table SA and SB outline the top 25 genes up-regulated and down-regulated by vitamin D and a heat map illustrating up-regulated and down-regulated genes. Table 4 outlines the biological processes and molecular functions modified by vitamin D treatment. Several of the identified pathways had significant relevance to proliferation, wound repair and apoptosis, so we tested the functional effects of vitamin D upon these important repair/protective processes.

    View this table:
    Table 4

    List of 30 statistically significant gene ontology (GO) terms implicated by differential expression of genes in day 3 epithelial (type II like) cells treated with vitamin D3 100 nM relative to untreated cells

    Effect of physiologically relevant doses of 25(OH)D3 upon primary human alveolar type II cells

    25(OH)D3 at physiologically relevant concentrations stimulated scratch wound repair, cell proliferation and attenuated soluble Fas ligand (sFasL)-mediated cell death (see figures 8⇓–10).

    Figure 8
    Figure 8

    Scratch wound repair response of primary human alveolar type II cells to 25(OH)D3. Wound area after 24 h was compared with baseline and expressed as fold change in wound area. Data represents experiments using cells from six separate lung resection specimens. Analysis of variance p=0.001.

    Figure 9
    Figure 9

    Proliferation of primary human ATII cells in response to physiological doses of 25(OH)D3 by bromodeoxyuridine incorporation. Experiments were performed using cells from four donors. Analysis of variance p=0.001.

    Figure 10
    Figure 10

    Cellular response to soluble Fas ligand (sFasL) 10 ng/mL induced cell death. Experiments were performed using ATII cells from four donors. 100 nmol/L 25(OH)D3 was added at the time of addition of sFasL.

    Discussion

    We have assessed the vitamin D status of a large cohort of patients with ARDS and a well-characterised group of patients at risk of ARDS, namely patients undergoing oesophagectomy. In ARDS cases, vitamin D deficiency was ubiquitous. Survivors of ARDS had significantly higher levels of vitamin D than non-survivors.

    Our finding of a 30% reduction in VDBP in patients with ARDS supports a role for either reduced production or increased losses as an explanation for some of the degree of deficiency seen. Equally the low observed levels of circulating 1,25(OH)2D in patients with ARDS suggests a problem with renal metabolism as this is probably the major source of circulating 1,25(OH)2D.23

    Several studies have suggested that vitamin D deficiency may be a risk factor for adverse outcome in pneumonia24 and lower respiratory tract infections in neonates.25 Other studies have suggested patients with sepsis have significant vitamin D deficiency.26 ,27 Our data suggests in the high-risk oesophagectomy group that vitamin D status is also a pre-existing risk factor for ARDS—especially when deficiency is severe. Patients undergoing oesophagectomy with severe preoperative vitamin D deficiency had greater risk of postoperative ARDS and increases in PiCCO measures of alveolar permeability than those with less severe deficiency.

    In our animal model of LPS-induced lung injury, vitamin D deficiency was associated with greater BALF cellular inflammation and cytokine release at 48 h. Increased epithelial damage and accumulation of apoptotic neutrophils was also evident. Mice that were vitamin D deficient became more hypoxic, suggesting physiologically worse lung injury.

    Our animal data is in keeping with recently published data in hamsters treated with LPS.28 In contrast, Klaff et al found reduced neutrophil chemotactic potential to the chemokine KC ex vivo in mice deficient in vitamin D but no differences in LPS-induced BALF neutrophilia. They used a 72 h time point and a much lower dose of LPS (2.5 µg), which we suggest accounts for the differences with our study.

    In both our human at-risk patients and the murine model, we have demonstrated evidence of increased permeability of the alveolar capillary barrier in response to one lung ventilation (EVLWI and PVPI) and LPS challenge respectively (PPI) when severe deficiency is present, suggesting that vitamin D might have protective effects on the alveolar epithelium as well as being anti-inflammatory. 1,25(OH)2D has been shown to induce DNA incorporation in human alveolar type II cells,29 but the effects of physiologically relevant doses of 25(OH)D have not been addressed upon type II cells previously. To address whether 25(OH)D3 has effects on ATII cells, we demonstrated considerable functional activity of a physiological dose of 25(OH)D3 by microarray analysis. Physiologically relevant doses of 25(OH)D3 stimulated wound repair, cellular proliferation and reduced sFasL-induced cell death. These in vitro experiments suggest that 25(OH)D3 may play a trophic role on adult human alveolar epithelial cells.

    This study has limitations. First, although we obtained blood from patients with ARDS as soon as possible following admission to ITU, we are unable to be sure that levels of 25(OH)D3 were low prior to the development of ARDS in that cohort or whether levels fall because of the development of ARDS. Second, our at-risk data from oesophagectomy patients has to be divided into severe deficiency and moderate deficiency because of the severity of vitamin D deficiency observed in that patient group. Third, our data in oesophagectomy patients’ needs validating in an additional significant cohort as well as in other patient groups at risk of ARDS. Finally, our comparison of EVLWI between our patients in BALTI prevention cohort versus our oesophagectomy patients in the open label vitamin D replacement study is a potential limitation. However, the translational protocol of assessments and the two centres in which those assessments were performed was the same between the two studies. We are currently conducting a randomised placebo controlled trial to confirm these results due to finish recruitment in mid-2015, which should further address this question.30

    Taken together, these data suggest that vitamin D deficiency is ubiquitous in patients with ARDS and relates to adverse outcome. In patients undergoing oesophagectomy, severe preoperative deficiency is associated with evidence of increased alveolar epithelial damage and EVLW accumulation as well as an increased risk of postoperative lung injury. Novel in vitro data further suggest a trophic and antiapoptotic role of physiologically relevant doses of 25(OH)D3 upon primary adult human alveolar epithelial cells. Finally, preoperative restoration of vitamin D levels in patients with oesophageal cancer who are at risk of ARDS resulted in significantly less accumulation of EVLW than in unsupplemented patients postoperatively.

    In conclusion, we suggest that clinical strategies should be developed to replete vitamin D levels in patients at risk of ARDS and this approach might also have value as a treatment for established ARDS.

    Acknowledgments

    We would like to thank the staff and patients of the Queen Elizabeth Hospital Birmingham and Heart of England NHS trust for their help in recruiting to and taking part in these studies. We would like to thank Teresa Melody and Amy Bradley for trial nurse support for the study.

    References

    1. ↵
      1. Parekh D,
      2. Dancer RC,
      3. Thickett DR
      . Acute lung injury. Clin Med 2011;11:615–18. doi:10.7861/clinmedicine.11-6-615
      OpenUrlFREE Full Text
    2. ↵
      1. van Schoor NM,
      2. Lips P
      . Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 2011;25:671–80. doi:10.1016/j.beem.2011.06.007
      OpenUrlCrossRef
    3. ↵
      1. Parekh D,
      2. Thickett DR,
      3. Turner AM
      . Vitamin D deficiency and acute lung injury. Inflamm Allergy Drug Targets 2013;12:253–61. doi:10.2174/18715281113129990049
      OpenUrlCrossRefPubMed
    4. ↵
      1. Remmelts HH,
      2. van de Garde EM,
      3. Meijvis SC, et al
      . Addition of vitamin d status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin Infect Dis 2012;55:1488–94. doi:10.1093/cid/cis751
      OpenUrlAbstract/FREE Full Text
    5. ↵
      1. Cannell JJ,
      2. Hollis BW
      . Use of vitamin D in clinical practice. Altern Med Rev 2008;13:6–20.
      OpenUrlPubMedWeb of Science
    6. ↵
      1. Amrein K,
      2. Schnedl C,
      3. Holl A, et al
      . Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA 2014;312:1520–30. doi:10.1001/jama.2014.13204
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      1. Kempker JA,
      2. Tangpricha V,
      3. Ziegler TR, et al
      . Vitamin D in sepsis: from basic science to clinical impact. Crit Care 2012;16:316. doi:10.1186/cc11252
      OpenUrlCrossRefPubMed
    8. ↵
      1. Froicu M,
      2. Cantorna MT
      . Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007;8:5. doi:10.1186/1471-2172-8-5
      OpenUrlCrossRefPubMed
    9. ↵
      1. Perkins GD,
      2. McAuley DF,
      3. Thickett DR, et al
      . The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173:281–7. doi:10.1164/rccm.200508-1302OC
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      1. Perkins GD,
      2. Gates S,
      3. Lamb SE, et al
      . Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials 2011;12:113. doi:10.1186/1745-6215-12-113
      OpenUrlCrossRefPubMed
    11. ↵
      1. Bernard GR,
      2. Artigas A,
      3. Brigham KL, et al
      . The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3 Pt 1):818–24. doi:10.1164/ajrccm.149.3.7509706
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      1. Nathani N,
      2. Perkins GD,
      3. Tunnicliffe W, et al
      . Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome. Crit Care 2008;12:R12. doi:10.1186/cc6785
      OpenUrlCrossRefPubMed
    13. ↵
      1. Thomas MK,
      2. Lloyd-Jones DM,
      3. Thadhani RI, et al
      . Hypovitaminosis D in Medical Inpatients. N Engl J Med 1998;338:777–83. doi:10.1056/NEJM199803193381201
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      1. Holick MF
      . Vitamin D Deficiency. N Engl J Med 2007;357:266–81. doi:10.1056/NEJMra070553
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      1. O'Kane CM,
      2. McKeown SW,
      3. Perkins GD, et al
      . Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009;37:2242–9. doi:10.1097/CCM.0b013e3181a5506c
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      1. Perkins GD,
      2. Gao F,
      3. Thickett DR
      . In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 2008;63:215–20. doi:10.1136/thx.2007.080382
      OpenUrlAbstract/FREE Full Text
    17. ↵
      1. Lax S,
      2. Wilson MR,
      3. Takata M, et al
      . Using a non-invasive assessment of lung injury in a murine model of acute lung injury. BMJ Open Respir Res 2014;1:e000014. doi:10.1136/bmjresp-2013-000014
      OpenUrlAbstract/FREE Full Text
    18. ↵
      1. Chishimba L,
      2. Thickett DR,
      3. Stockley RA, et al
      . The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 2010;65:456–62. doi:10.1136/thx.2009.128793
      OpenUrlAbstract/FREE Full Text
    19. ↵
      1. Craig TR,
      2. Duffy MJ,
      3. Shyamsundar M, et al
      . Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury. Crit Care Med 2010;38:114–20. doi:10.1097/CCM.0b013e3181b43050
      OpenUrlCrossRefPubMedWeb of Science
    20. ↵
      1. Calfee CS,
      2. Ware LB,
      3. Eisner MD, et al
      . Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008;63:1083–9. doi:10.1136/thx.2008.095588
      OpenUrlAbstract/FREE Full Text
    21. ↵
      1. Eisner MD,
      2. Parsons P,
      3. Matthay MA, et al
      . Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003;58:983–8. doi:10.1136/thorax.58.11.983
      OpenUrlAbstract/FREE Full Text
    22. ↵
      1. Ware LB,
      2. Koyama T,
      3. Billheimer DD, et al
      . Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010;137:288–96. doi:10.1378/chest.09-1484
      OpenUrlCrossRefPubMedWeb of Science
    23. ↵
      1. Hewison M
      . Vitamin D and immune function: an overview. Proc Nutr Soc 2012;71:50–61. doi:10.1017/S0029665111001650
      OpenUrlCrossRefPubMed
    24. ↵
      1. Leow L,
      2. Simpson T,
      3. Cursons R, et al
      . Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 2011;16:611–16. doi:10.1111/j.1440-1843.2011.01924.x
      OpenUrlCrossRefPubMedWeb of Science
    25. ↵
      1. Mohamed WA,
      2. Al-Shehri MA
      . Cord blood 25-hydroxyvitamin d levels and the risk of acute lower respiratory tract infection in early childhood. J Trop Pediatr 2013;59:29–35. doi:10.1093/tropej/fms042
      OpenUrlAbstract/FREE Full Text
    26. ↵
      1. Grant WB
      . Low vitamin D status may predict women at risk of sepsis associated with delivery. BJOG 2012;119:1018–19; author reply 19–20. doi:10.1111/j.1471-0528.2012.03361.x
      OpenUrlPubMed
    27. ↵
      1. Flynn L,
      2. Zimmerman LH,
      3. McNorton K, et al
      . Effects of vitamin D deficiency in critically ill surgical patients. Am J Surg 2012;203:379–82; discussion 82. doi:10.1016/j.amjsurg.2011.09.012
      OpenUrlCrossRefPubMed
    28. ↵
      1. Takano Y,
      2. Mitsuhashi H,
      3. Ueno K
      . 1alpha,25-Dihydroxyvitamin D(3) inhibits neutrophil recruitment in hamster model of acute lung injury. Steroids 2011;76:1305–9. doi:10.1016/j.steroids.2011.06.009
      OpenUrlCrossRefPubMed
    29. ↵
      1. Edelson JD,
      2. Chan S,
      3. Jassal D, et al
      . Vitamin D stimulates DNA synthesis in alveolar type-II cells. Biochim Biophys Acta 1994;1221:159–66. doi:10.1016/0167-4889(94)90008-6
      OpenUrlPubMed
    30. ↵
      1. Parekh D,
      2. Dancer RC,
      3. Lax S, et al
      . Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials 2013;14:100. doi:10.1186/1745-6215-14-100
      OpenUrlCrossRefPubMed

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

      Files in this Data Supplement:

    Footnotes

    • RCAD and DP are joint first author of this paper.

    • Correction notice This article has been corrected since it was published Online First. The author's name William M Fraser was incorrect and should be William D Fraser.

    • Contributors RCAD and DP are joint first authors. DRT, FG, ARM, PMS, MSC, WMF and GDP designed the study. SL, VD, SZ, CRB, DP, BN, RM, AMT and ES recruited the patients and undertook lab analysis/animal work. WW, PMS, WMF, KBC and MSC provided expert advice in their specialist areas. All authors contributed to the writing of the paper. DT is the guarantor of the data.

    • Funding These studies were funded by the Wellcome trust (DRT, PMS, MSC, SL), QEHB charities (RCAD, VD, DRT), the Medical Research Council UK (DRT, DP, RCAD) and the NIHR (DP, DRT, GDP). DB was funded by an ERS long-term training fellowship and a Marie Curie Intra-European Fellowship.

    • Competing interests None declared.

    • Patient consent Obtained

    • Ethics approval NHS LREC West midlands and all clinical investigations were conducted according to Declaration of Helsinki principles.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement The microarray dataset outlined in this paper is freely available to search on PubMed GEOSET.

    Linked Articles

    • Airwaves
      Highlights from this issue
      Andrew Bush Ian Pavord
      Thorax 2015; 70 i-i Published Online First: 12 Jun 2015. doi: 10.1136/thoraxjnl-2015-207321